Summary Siamab Therapeutics Inc (Siamab Therapeutics), formerly Sialix Inc, is a biopharmaceutical company that focuses on the development of novel medicines targeting cancer-specific carbohydrate antigens.Its ST1 program targets a tumor associated carbohydrate antigen present in solid tumors.
Siamab Therapeutics developed a technology platform that enables the discovery of large numbers of highly specific anti-TACA (tumor associated carbohydrate antigens) antibodies to kill cancer cells and also re-engage the immune system and overcome chemo-resistance.The company develops therapies in the areas of abnormal carbohydrates, glycans, ovarian, pancreatic, prostate, colon, breast and other solid tumors. Siamab Therapeutics is headquartered in Newton, Massachusetts, the US.
Siamab Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The ePRO, ePatient diaries, and eCOA market in Asia Pacific is expected to grow from US$ 348.8 million in 2021 to US$ 964.2 million by 2028; it is estimated to grow at a CAGR of 15.6% from 2021 to 2028. Healthcare systems are experiencing a rise in consumer engagement worldwide. In developing countries, health care systems are becoming more...
The Global Microbiome Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Microbiome partnering deals Disclosed headlines, upfronts, milestones and royalties by...
Aryl Hydrocarbon Receptor - Drugs In Development, 2021 Summary According to the recently published report ’Aryl Hydrocarbon Receptor - Drugs In Development, 2021’; Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 29 molecules....
Executive Summary Global Hexamethyldisilazane Market was valued at USD 202.32 Million and xx Kilotonne by volume in the year 2020. Hexamethyldisilane (HMDS) is an organosilicon compound used as a reagent or precursor to bases and is primarily used as a silylating agent in the process of manufacturing pharmaceutical drugs...
The global microplate systems market size is projected to reach USD 1,170 million by 2026 from USD 927 million in 2021, at a CAGR of 4.8% from 2021 to 2026. Growth in this market is driven by the increasing R&D expenditure in the pharmaceutical industry, increasing focus on miniaturization, and the growing prevalence of diseases Microplate...
The global pharmaceutical intermediates market is expected to reach US$ 37,290.33 million in 2028 from US$ 27,356.70 million in 2020. The market is estimated to grow with a CAGR of 3.95% during 2020-2028. Countries in Asia Pacific are emerging as attractive outsourcing locations for pharmaceuticals and biopharmaceuticals industries. Low manufacturing...
120 pages •
By Infiniti Research Limited
• May 2021
Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market 2021-2025 The analyst has been monitoring the contract development and manufacturing organization (CDMO) outsourcing market and it is poised to grow by $ 64.44 bn during 2021-2025, progressing at a CAGR of over 11% during the forecast period....
REPORT OBJECTIVES The report “Fish Oil Products Market: Global Market Intelligence (2020-2030) provides market intelligence on the different market segments, based on Market Dynamics, Distribution Channel, Product type, and geography. Market size and forecast (2020-2030) has been provided in the report. The primary objectives...
Europe Amaranth Market Size, Share & Trends Analysis Report By Category (Organic, Conventional), By Product (Seed, Oil, Leaf, Flour), By Application (Food & Beverages, Personal Care), And Segment Forecasts, 2021 - 2028
Europe Amaranth Market Growth & Trends
The Europe amaranth market size...
This IDC Perspective provides IDC Health Insights' overview of key IT deals, news, and digital initiatives in the European life sciences and pharma industries in Q1 2021. In the evolving COVID-19 scenario, it is critical for European life sciences companies and their technology suppliers to closely follow the fast-moving trends and developments...
Medical Technology Density
Prescription Drug Sales
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.